The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

@article{Borgstrm2009TheCO,
  title={The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis},
  author={Fredrik Borgstr{\"o}m and Oskar Str{\"o}m and J. Coelho and H Johansson and Anders Od{\'e}n and Eugene V. McCloskey and J. A. Kanis},
  journal={Osteoporosis International},
  year={2009},
  volume={21},
  pages={339-349}
}
The cost-effectiveness of strontium ranelate was compared to no treatment in UK women using the FRAX® algorithm for fracture risk assessment. At a willingness-to-pay of £30,000 per quality-adjusted life-year (QALY), strontium ranelate was generally cost-effective in women with prior fracture at the threshold of osteoporosis from an age of 65 years. The objectives of the study were to estimate the cost-effectiveness of strontium ranelate in the UK for the treatment of osteoporosis and to… CONTINUE READING

From This Paper

Topics from this paper.
14 Citations
64 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 64 references

on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level

  • J Kanis
  • Technical Report,
  • 2008
Highly Influential
4 Excerpts

a systematic review

  • M Lloyd-Jones, Wilkinson, A Adverse effects, persistence with therapy in patients taking oral alendronate, etidronate or risedronate
  • NHS R & D HTA ScHARR 348 Osteoporos Int
  • 2010
1 Excerpt

first two case reports

  • AP Jonville-Bera, B Crickx, L Aaron, I Hartingh, syndrome Autret-Leca E Strontium ranelate-induced DRESS
  • Allergy 64:658–659 Osteoporos Int
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…